SRRK Earnings Date: Nov 10, 2026 (Estimated) — Scholar Rock Holding Corporation
NASDAQ · Healthcare · Biotechnology
Updated
When is SRRK's next earnings date?
Scholar Rock Holding Corporation (SRRK) is expected to report Q3 2026 earnings on Tuesday, November 10, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.85 on revenue of $303,929.
How did SRRK do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Scholar Rock Holding Corporation posted EPS of -$0.84 versus the -$0.84 estimate, a beat of 0.0%. Revenue was $0 against a $70,000 estimate. The stock's 1-day post-earnings move was +10.0%.
How much does SRRK stock move after earnings?
SRRK beat EPS estimates in 2 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.8% (up or down) in the day after earnings.
About Scholar Rock Holding Corporation
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.84 | -0.84 | +0.00% | $0 | ✅ Beat | +9.96% | +12.43% | +16.86% |
| 2026-05-07 | Q1 2026 | -0.79 | -0.83 | -5.06% | $0 | ❌ Miss | -1.40% | +6.50% | -5.96% |
| 2026-03-03 | Q4 2025 | -0.87 | -0.88 | -1.15% | $0 | ❌ Miss | +1.91% | +1.72% | +13.06% |
| 2025-11-14 | Q3 2025 | -0.85 | -0.90 | -5.88% | $0 | ❌ Miss | +24.41% | +26.44% | +50.45% |
| 2025-08-06 | Q2 2025 | -0.66 | -0.98 | -48.48% | $0 | ❌ Miss | -6.40% | -12.93% | -12.28% |
| 2025-02-27 | Q4 2024 | -0.63 | -0.61 | +3.17% | $0 | ✅ Beat | -2.86% | -2.38% | -9.89% |
| 2024-11-12 | Q3 2024 | -0.60 | -0.66 | -10.00% | $0 | ❌ Miss | -5.29% | -6.29% | +49.84% |
| 2024-05-07 | Q1 2024 | -0.48 | -0.59 | -22.92% | $0 | ❌ Miss | -2.46% | -9.43% | -34.73% |
Showing last 8 quarters.